May 6, 2020
DongWha Pharm’s plans testing new drug candidate to treat COVID-19
DongWha Pharm’s said it is getting ready for second phase of clinical trials of new drug candidate DW2008 to treat COVID-19.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 6, 2020
Spruce Biosciences has new CFO and new VP pharma development and manufacturing
Spruce Biosciences has announced the appointments of Samir Gharib, MBA, CPA, as Chief Financial Officer (CFO), and Dasharatha Reddy, Ph.D., as Vice President, Pharmaceutical Development and Manufacturing.
May 6, 2020
Alnylam Pharmaceuticals ends Q1 2020 with net product revenues of $71.94M
Alnylam Pharmaceuticals ends Q1 2020 with net product revenues of $71.94M
May 6, 2020
Acerus’s Norma Beauchamp in resignation as director
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) announced that Norma Beauchamp has resigned as a member of…
May 6, 2020
Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate COVID-19 Clinical Trial
Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19 MONTREAL–(BUSINESS WIRE)–Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company,…
May 6, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
— First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3 — UTRECHT, The Netherlands–(BUSINESS…
May 6, 2020
Dr. Reddy’s Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
May 5, 2020
Clovis reports net loss for the Q1 2020 of $99.3 million
Clovis reported a net loss for the first quarter of 2020 of $99.3 million, or ($1.39) per share, compared to the net loss for the first quarter of 2019 which was $86.4 million, or ($1.63) per share. Net loss for the first quarter of 2020 included share-based compensation expense of $13.0 million, compared to $13.6 million for the first quarter of 2019.
May 5, 2020
Sanofi, Regeneron plan submitting for Libtayo
Sanofi and Regeneron plan to submit this year their product Libtayo, which has shown in a pivotal trial with certain patients with advanced basal cell carcinoma, that it has meaningful and durable responses.
May 5, 2020
Deciphera Pharmaceuticals ends Q1 with $691.5M, net loss $72.8M
Deciphera Pharmaceuticals has ended the first quarter 2020 with cash, cash equivalents and marketable securities of $691.5 Million, with cash runway expected into the second half of 2022, and posts net loss of $72.8 million.